The Pathway PV Atherectomy system is designed to treat the entire spectrum of disease found in the PAD patient. The system has expandable, rotating scraping blades with aspiration for preemptive removal of both hard and soft plaque. The Pathway PV Atherectomy system reportedly provides simple set-up and easy operation to maximize effectiveness and minimize procedure time.

The Pie Medical Imaging CAAS (Cardiovascular Angiography Analysis System) QCA 3D software offers automated detection and 3D analysis of single and bifurcated coronary arteries from angiographic X-ray projection images. Out-of-plane magnification and foreshortening errors are reportedly minimized by calculating true geometric shape in 3D space from two or more 2D X-ray projections.

The AngioJet Rheolytic Thrombectomy System included a range of specialized catheters available, allowing the physician to choose the length, diameter and clot removal power appropriate for the patient.

The BRANSIST safire VC17 ceiling-mounted vascular package is a digital angiography system that features a 17 by 17-inch direct-conversion FPD, reportedly the largest in its class. The system is designed with not only high image quality, but also the optimal image quality for the various complex interventional procedures over the extensive field of views available.

Stereotaxis’s suite of proprietary magnetic coronary guidewires including CRONUS, ASSERT and TITAN, suitable for use in interventional cardiology procedures for the introduction and placement of over-the-wire therapeutic devices, such as biventricular pacing leads used in cardiac resynchronization therapy or stents used in percutaneous coronary interventions.

Stereotaxis will feature its Stereotaxis magnetic navigation system, designed to allow physicians to more effectively navigate catheters, guidewires and other magnetic interventional devices.

Computer control automates the movement of these devices, allowing for safety and efficiency.

Genesis Medical Interventional Inc. developed the F.A.S.T. Funnel Catheter line of proximal occlusion funnel catheters for embolic protection.

August 27, 2008 - Cordis Corp. today said it received CE mark approval to market the CYPHER SELECT Plus Sirolimus-eluting coronary stent for the treatment of acute myocardial infarction (AMI).

CE mark approval means the product has been deemed safe and effective for treatment of AMI and can now be promoted for this indication in all member states of the European Union (EU), European Economic Area and Switzerland.

August 27, 2008 - The Children's Hospital at Montefiore (CHAM) in the Bronx recently received approval as a pediatric heart transplant center by the New York State Department of Health.

On the strength of a newly recruited pediatric cardiology team, specialists at CHAM can now treat any congenital or acquired heart abnormality in children and adolescents.

August 27, 2008 - XDx Inc. said today it received market clearance from the FDA for AlloMap Molecular Expression Testing, a noninvasive, multi-gene molecular diagnostics blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing.

XDx is the first U.S. molecular diagnostics company to obtain FDA clearance of an in vitro diagnostic multivariate index assay (IVDMIA) for use in transplant management.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now